Sr. Director of Market Access & Health Policy for Rare/Orphan CNS/Epilepsy start-up. Responsible for Market Access, Patient Assistance, HUB Services, and Specialty Pharmacy distribution. Presently overseeing organizational structure development, staffing, vendor selection and contract negotiation. Developing and Implementing Payer access strategy to reduce hurdles to patient access, which includes pricing & PAP decisions, developing account engagement plan of action, and supporting interdepartmental group process builds. Launched ANDA and NDA pharmacy benefit specialty assets.

Corporate Account Director, Payer Markets, reporting to the US Lead of Corporate Accounts: Responsible for preparing the payer market for the launch of a rare fungal disease asset; designing and executing market access strategies, determining resource allocation, and collaboration/negotiation across Commercial, Medicare, Medicaid, VA/DOD, and Indian Health Services, enabling profitable access for F2G’s Olorofim and all future pipeline products & indications within the US.

Rare/Orphan Epilepsy disease state education (Dravet & Lennox Gastaut Syndromes), securing appropriate payer coverage policies, and ensuring payer approval for patient benefit and speed to therapy through REMS program. Pre-launched Rare Pediatric Disease Designation and FDA Priority Review Status for the epilepsy medication, FINTEPLA and pre-launch for TK2d for Ultra Rare Mitochondrial Deficiency DiseaseExceeded strategic goals of 90% acceptable payer coverage policies, targeted customer engagement outcomes, and patient time-to-approval targets

Secured profitable access positions through contract negotiations for primary care portfolio and enhanced medical policy criteria for Orphan/Rare disease, infusible autoimmune & ophthalmic specialty, and inflammatory therapies for National & Regional commercial, Medicare, and Medicaid PBMs & health plans within the Western United States. Launched TEPEZZA, one of the top rare disease launches in history, achieving one of the strongest initial approval rates and utilization of this blockbuster, life-changing medicine. Drove historic sales performance and patient access numbers for the orphan specialty infusible drug KRYSTEXXA by obtaining positive medical policy changes with key payers.Recognized as the first Account Director in the company to achieve medical policy changes at targeted health plans to conform with updated guidelines for a key specialty infusible orphan drug and exceeded all MBOs

Responsible for driving Iroko Pharmaceuticals novel NSAID therapy products revenue with national Commercial health plans, PBMs, Employers, Workers Compensation & Government (Medicare Part D, VA/DoD & state Medicaid) payers. Provide Marketing and Sales leadership with key market intelligence & reimbursement strategy to minimum access barriers for Iroko Pharmaceuticals product. Accountable for field sales & third party Account Managers Managed Markets alignment.Significantly exceeded all MBOs.

Introduced company and launched new oral therapies for Epilepsy and rare Lennox Gastaut Syndrome pipeline to National/Regional Commercial, Medicare, and Medicaid accounts while obtaining profitable access positions. Identified and recommended Managed Markets support, analytics & financial assessment, discovery and support program structures.Met and exceeded all MBOs.

Provided consultative services for programs pertaining to co-pay assistance, specialty pharmacy services, contracting platforms, bidding and RFP processes to large national & regional managed care payers.

Provider of Home Healthcare Services.Lead 14 Account Executives and Nurse Care Transition Coordinators in establishing and developing new business contacts; maintained current relationships; developed and implemented a sales and marketing plan to exceed sales goals. Developed rapport and built executive business relationships with hospitals, nursing homes, assisted living, independent living facilities, physician practices, and other long term care facilities to become their home health company of choice.

Provided consultative services for bidding and RFP processes pertaining to large national & regional managed care payers

Pre-approval opportunity with upstart urology & oncology biotech company.Became product expert for pre-launch oncology products. Managed Care point person on sales management advisory team for all pre-launch activities with customers and internal constituents. Leadership together for mutual business planning pre-launch strategies and contractual commitments. Developed and conducted pipeline presentations for all targeted payers. Confirmed clinical download follow-up meetings for PBMs, MCOs, Medicare, and State Medicaid programs. Developed contracting strategies and support programs to maximize planned profitable access positions.

Negotiated and contracted for entire company portfolio of products. Commercial, Medicare and Medicaid books of business for key accounts including Express Scripts, CVS Caremark, Kaiser Permanente, MedImpact, Humana, The Regence Group, and Envision Rx. Managed 7 Regional Account Managers while additionally coordinating and implementing sales and marketing pull-through programs with nine Regional Account Directors and their teams of over 50 Regional Account Mangers to maximize product formulary positions while helping the plans achieve their business objectives. Multiple President's Club nominee

Developed positive business relationships with key organ transplant programs and teams within Arizona, Colorado and New Mexico

Launched Rapamune (novel new antirejection therapy) for solid organ transplant patients. Provided input and leadership for design. Instrumental in execution of roll-out of sales force, implementation of marketing plan and launch.

Developed and rolled out managed markets strategies and tactics for Wyeth portfolio of products nationally in support of over 60 Regional Account Managers, 12 National Account Directors and their leadership.

Internally recruited to formulate and execute the business development, marketing, contracting / contract compliance, and rebate strategies to achieve formulary access for Wyeth products within regional MCO and federal government (DOD / VA) accounts. Represented large product portfolio, including Enbrel, Protonix, Effexor XR, Altace, Zosyn, and Enbrel. Interfaced with C-level executives and Medical / Pharmacy Directors during presentations and contract negotiations. Collaborated with Brand Management, Sales Directors, and National Account Managers on pull-through initiatives and implemented programs at the field level. Developed Key Opinion Leaders to serve as product advocates and train field team on reimbursement strategies. Managed key accounts in Arizona, New Mexico, Utah, and Colorado

Managed teams of diverse individuals by identifying unique talents and implementing a customized development plan for each. Successfully launched 3 products within district. Product line included hormone replacement therapy, oral contraceptives, arthritis and pain management, antidepressant, flu vaccine and cardiovascular. Geography included AZ, CA, ID, NV, UT, and WY.

Trained new sales force of over 800 new sales representatives while maintaining territory performance within top 12% of the company.

Consistantly ranked within the top 15% of the nation in this near Northwest Chicago territory. Represented Women's Health, Cardiovascular, CNS, Vaccines, and Hospital injectables.